Avexa Limited is an Australia-based biotechnology company with a focus on discovery, development and commercialization of small molecules for the treatment of infectious diseases. The Company is engaged in drug development programs with establishment and support of an early access program (EAP) for apricitabine (ATC). It is also engaged in monitoring the performance of its investments, particularly the North Pratt coalmine in Alabama, the United States. The Company operates through two segments: anti-infective research and development, and investments. The Company's projects include ATC for the treatment of drug resistant human immunodeficiency virus (HIV), an HIV Integrase program and an antibiotic program for antibiotic-resistant bacterial infections. Its HIV integrase project has targeted once daily administration without a pharmacological booster, and activity against resistant mutants. It has two pre-clinical drugs: a suite of HIV-integrase inhibitors and AVX13616, an antibiotic.